Titration

Galleon Gold Extends Gold Mineralization on Eastern Flank at West Cache Project

Wednesday, July 21, 2021 - 12:45pm

Toronto, Ontario--(Newsfile Corp. - July 21, 2021) - Galleon Gold Corp. (TSXV: GGO) (the "Company" or "Galleon Gold") is pleased to announce final assay results from the 2021 East Pit extension drill program at the Company's 100% owned West Cache Gold Project, Timmins, Ontario.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - July 21, 2021) - Galleon Gold Corp. (TSXV: GGO) (the "Company" or "Galleon Gold") is pleased to announce final assay results from the 2021 East Pit extension drill program at the Company's 100% owned West Cache Gold Project, Timmins, Ontario.
  • With all assays now complete for this area, results continue to confirm the easterly extension of multiple gold zones.
  • This was the second set of holes targeting the eastern margins of our known mineralization, and results confirm the trend is open-ended and our pit and underground potential continues to grow.
  • Close-up photos of the East Extension mineralization with corresponding gold grades can be seen in Figure 5.

Vyant Bio Announces Issuance of Key Patent for High-Throughput Optical Assay of Human Mixed Cell Population Spheroids

Tuesday, July 13, 2021 - 1:20pm

11054408, titled High Throughput Optical Assay of Human Mixed Cell Population Spheroids by the United States Patent and Trademark Office (USPTO).

Key Points: 
  • 11054408, titled High Throughput Optical Assay of Human Mixed Cell Population Spheroids by the United States Patent and Trademark Office (USPTO).
  • The issuance of the 11054408 patent is the third patent granted to StemoniX: additional applications are currently pending worldwide.
  • Human iPSCs offer many advantages over recombinant cell lines or primary rodent cells for use in drug screening.
  • Vyant Bio, Inc. (Vyant Bio, the Company) (Nasdaq: VYNT) is emerging as an advanced biotechnology drug discovery company.

Nephros Announces Acquisition of GenArraytion, Inc.

Monday, July 12, 2021 - 12:30pm

This acquisition will give Nephros access to GenArraytions many proprietary assays, multiplexing technology, and selection methods for detecting waterborne pathogens and other microorganisms using Polymerase Chain Reaction (PCR) technology.

Key Points: 
  • This acquisition will give Nephros access to GenArraytions many proprietary assays, multiplexing technology, and selection methods for detecting waterborne pathogens and other microorganisms using Polymerase Chain Reaction (PCR) technology.
  • GenArraytions assets will be integrated into the Nephros Pathogen Detection Systems platform.
  • I am very much looking forward to partnering with the Nephros team and realizing our shared vision around water safety."
  • Nephros is a leading water technology company in medical and commercial water purification and pathogen detection, headquartered in the USA.

Spanish Mountain Gold Reports Assay Results from Resource Expansion Program: Multiple Long Intercepts in All Four Tested Areas

Tuesday, July 6, 2021 - 1:30pm

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2021) - Spanish Mountain Gold Ltd. (TSXV: SPA) (the "Company") is pleased to announce the assay results from the latest resource expansion program for the Spanish Mountain Gold Project (the "Project") located in British Columbia, Canada.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - July 6, 2021) - Spanish Mountain Gold Ltd. (TSXV: SPA) (the "Company") is pleased to announce the assay results from the latest resource expansion program for the Spanish Mountain Gold Project (the "Project") located in British Columbia, Canada.
  • Notably, the assay results report long intercepts (up to 68.58 m in length) in all four tested areas with grades higher than the economic cut-off established in the latest resource estimate (published along with the PFS).
  • The Company has retained Discovery Consultants of Vernon, BC, to monitor independently the quality control and quality assurance (QC/QA) data on the Spanish Mountain Gold Project.
  • Spanish Mountain Gold Ltd. is focused on advancing its 100%-owned Spanish Mountain gold project in southern central British Columbia.

Axiom Presents "Unified Platforms: How to Address the Complexity of Oncology Studies to Better Support Your Sites" at Clinical Operations in Oncology Trials 2021

Thursday, June 24, 2021 - 2:59pm

They will share their expertise and highlight site-level operational needs of oncology studies, as well as how a unified platform can promote study accuracy, visibility and task automation.

Key Points: 
  • They will share their expertise and highlight site-level operational needs of oncology studies, as well as how a unified platform can promote study accuracy, visibility and task automation.
  • Key elements that bring complexity to oncology studies include enrollment and eligibility, patient scheduling and dose titration, as well as SRC readiness, Zarubick remarks.
  • A unified platform such as Axioms Fusion eClinical Suite can also serve as the connected hub for your oncology trial, DiFruscia contributes.
  • Since 2001, Axiom has delivered data-driven, powerful and cost-effective eClinical Solutions and Services dedicated to small-to-medium life science companies.

Amalgam Rx™ Receives CE Mark for Basal Insulin Titration

Wednesday, June 16, 2021 - 2:43pm

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing it has achieved the Conformit Europenne (CE) Mark for its insulin titration application, iSage Rx and its white-labeled variants.

Key Points: 
  • Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing it has achieved the Conformit Europenne (CE) Mark for its insulin titration application, iSage Rx and its white-labeled variants.
  • View the full release here: https://www.businesswire.com/news/home/20210616005524/en/
    Amalgam Rx Receives CE Mark for Basal Insulin Titration (Graphic: Business Wire)
    With this CE Mark, iSage Rxs capacity to support the titration of all basal insulins and enable connectivity to the leading Bluetooth-enabled blood glucose meters from Roche, Lifescan, and Ascensia, is now cleared for the European market.
  • In early clinical studies, the iSage Rx app has demonstrated the ability to improve patients glucose levels by helping them reach the appropriate level of basal insulin.
  • Amalgam is the manufacturer of the iSage Rx app and white-labeled variants, the first prescription-only mobile application for the automated titration of all brands of basal insulin to receive market authorization in the United States, EU, and Brazil.

Sanatana Gold Rush Project - Initial Assay Results Return 2m @ 2.22g/t Au

Wednesday, June 16, 2021 - 1:44pm

Buddy Doyle, President said, "The scout drilling program was initiated to gain a rapid understanding of the type and styles of mineralization on the Gold Rush property.

Key Points: 
  • Buddy Doyle, President said, "The scout drilling program was initiated to gain a rapid understanding of the type and styles of mineralization on the Gold Rush property.
  • The assay results will determine which prospects to focus further work on.
  • Additionally the results will help us to understand what are the main controls of the mineralization at the Gold Rush Project.
  • Assays have been returned for the North Vein prospect and we report a 2.22g/t Au interval in Drill hole NV-2021-03, 2m from 51m to 53m.

Safeguard DNA Diagnostics Launches Rhinostics Dry Collection Swabs for COVID Testing as Primary Collection Devices for Its Laboratories in the Philippines

Wednesday, June 9, 2021 - 1:00pm

Safeguard DNA Diagnostics Inc, SDDI, one of the largest chains of infectious disease laboratories in the Philippines, has introduced COVID sample collection using the Rhinostics dry nasal and nasopharyngeal collection swabs.

Key Points: 
  • Safeguard DNA Diagnostics Inc, SDDI, one of the largest chains of infectious disease laboratories in the Philippines, has introduced COVID sample collection using the Rhinostics dry nasal and nasopharyngeal collection swabs.
  • View the full release here: https://www.businesswire.com/news/home/20210609005070/en/
    Rhinostics innovative dry collection swabs offer comfortable nasal or nasoharyngeal collection, dry shipment, and sample concentration for better assay performance.
  • The dry swabs are more robust and offer lower risk for contamination during collection and transport than VTM and saliva collection devices.
  • The Rhinostics suite of collection products are registered as Class I exempt medical devices with the FDA and are available for purchase.

Worldwide Cell-Based Assays Industry to 2026 - Featuring Charles River Laboratories, Danaher and Lonza Among Others - ResearchAndMarkets.com

Thursday, May 27, 2021 - 10:07am

Then further based on end-users, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, and Contract Research Organizations.

Key Points: 
  • Then further based on end-users, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, and Contract Research Organizations.
  • This is due to the increasing demand for new drugs to globally treat various diseases among the rising elderly population.
  • In the regional market of cell-based assays, the North American region has occupied the market's substantial share.
  • Cell-based assays occupy various advantages over conventional biochemical assays and animal models, and these advantages have majorly driven the rising demand for these assays in the present years.

ProMIS Neurosciences initiates commercialization of COVID-19 serology assay

Tuesday, May 25, 2021 - 12:30pm

I am delighted to lead this opportunity on behalf of ProMIS Neurosciences, stated Owen Dempsey.

Key Points: 
  • I am delighted to lead this opportunity on behalf of ProMIS Neurosciences, stated Owen Dempsey.
  • Our initial focus will be on commercialization to the medical and public health community, vaccine developers, pharmaceutical companies, governmental agencies and other organizations.
  • This advanced serology test developed by ProMIS Neurosciences measures not only serum antibodies to SARS-CoV-2, the novel coronavirus causing COVID-19, but also their protective activity against infection.
  • Additional variants can be added to the assay as they are identified.The assay utilizes an advanced, high-throughput, sensitive and accurate surface plasmon resonance (SPR) technology as opposed to traditionalELISA (enzyme-linked immunosorbent assay) methods.